膽道腫瘤市場規模、佔有率和成長分析：按腫瘤類型、治療方法、分期、最終用戶、通路和地區分類－2026-2033年產業預測

2024 年全球膽道腫瘤市場價值為 18.2 億美元，預計到 2025 年將成長至 20.1 億美元，到 2033 年將成長至 45.2 億美元，在預測期（2026-2033 年）內複合年成長率為 10.62%。

全球膽道腫瘤市場涵蓋了廣泛的診斷方法、手術器械和標靶治療，旨在治療膽管和膽囊惡性腫瘤。由於人口老化和現代生活方式導致的死亡率和發病率上升，該市場的重要性日益凸顯。早期因檢測延遲而帶來的挑戰，已透過超音波和次世代定序等技術進步得到緩解，從而使重點轉向精準醫療。關鍵成長要素包括針對FGFR2融合和IDH1突變等基因突變的大量標靶治療，這些療法正在改善患者的治療效果。這些進步正在推動癌症治療中心採用這些療法，刺激對多重檢測的需求，並促進對診斷技術的投資，從而擴大新興經濟體和全球經濟體的整體市場規模。

全球膽道腫瘤市場成長要素

膽道腫瘤在各地發病率的不斷上升凸顯了製定有效治療策略的迫切需求，促使醫療專業人員拓展治療選擇並採用多學科綜合管理模式。患者和臨床醫生對膽道腫瘤的認知不斷提高，加速了早期診斷，並鼓勵積極尋求成熟療法和創新療法。這一趨勢不僅縮短了研發週期，也加強了市場參與企業的經銷網路，進一步推動了全球市場成長。此外，產學合作的加強、知識共用的增加以及法規核准流程的加快，也顯著促進了膽道腫瘤市場的整體發展勢頭。

全球膽道腫瘤市場的限制因素

全球膽道腫瘤市場面臨嚴峻挑戰，標靶治療的高昂費用對患者和醫療系統都造成了沉重的經濟負擔。這些高昂的費用往往阻礙了先進療法的普及，迫使醫療機構傾向傳統療法而非創新療法。這一趨勢限制了製造商的收入潛力，並對其新產品研發投入能力產生了負面影響。此外，這些經濟負擔也會影響醫療政策的製定，導致在將昂貴療法納入常規診療時採取更謹慎的態度，最終限制了整體市場的成長前景。

全球膽道腫瘤市場趨勢

全球膽道腫瘤市場正經歷整合基因組分析的顯著轉變，顯著提高了患者分子特徵的準確性。這項進步使醫療服務提供者能夠制定個人化的治療策略，從而在改善治療效果的同時減少副作用。因此，製藥公司正日益專注於拓展其標靶治療產品線，而診斷公司則投資開發可靠的伴隨診斷檢測，從而建立一個協作生態系統，加速各地區的藥物交付。這種協同作用不僅簡化了臨床醫師的決策流程，也符合保險公司在膽道腫瘤管理中實施以成本效益和療效為導向的支付模式的目標。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球膽道腫瘤市場規模：依腫瘤類型分類

• 膽管癌（CCA）
• 膽囊癌
• 乳頭狀癌

全球膽道腫瘤市場規模：依治療方式分類

• 化療（Gemcitabine+Cisplatin）
• 標靶治療（FGFR2、IDH1）
• 免疫療法

全球膽道腫瘤市場規模：依分期分類

• 地點
• 局部進展
• 轉移性

全球膽道腫瘤市場規模：依最終用戶分類

• 腫瘤中心
• 醫院

全球膽道腫瘤市場規模：依通路分類

• 醫院藥房
• 專科藥房

全球膽道腫瘤市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Incyte Corporation（Pemigatinib）
• AstraZeneca（Imfinzi）
• Agios Pharmaceuticals（Ivosidenib）
• Bristol Myers Squibb
• Merck & Co.
• Roche
• QED Therapeutics（Infigratinib）
• Deciphera Pharmaceuticals
• Relay Therapeutics
• Basilea Pharmaceutica
• Eisai Co.
• Takeda Pharmaceutical
• Zymeworks
• TransEnterix
• Turning Point Therapeutics（BMS）
• Elevation Oncology
• Inhibrx Inc.
• Pieris Pharmaceuticals
• Prelude Therapeutics
• G1 Therapeutics

結論與建議

Global Biliary Tumor Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 2.01 Billion in 2025 to USD 4.52 Billion by 2033, growing at a CAGR of 10.62% during the forecast period (2026-2033).

The global biliary tumor market encompasses a range of diagnostics, surgical tools, and targeted therapies aimed at treating malignancies affecting the bile ducts and gallbladder. This market is increasingly pivotal due to high mortality rates and rising incidences linked to aging populations and modern lifestyles. The initial challenges posed by late detection have been mitigated by advancements like endoscopic ultrasound and next-generation sequencing, shifting the focus toward precision medicine. Key growth drivers include a robust pipeline of targeted therapies that address genetic mutations such as FGFR2 fusions and IDH1 mutations, leading to improved patient outcomes. This evolution fosters increased adoption among oncology centers, stimulates demand for multiplex assays, and encourages investment in diagnostics, which fuels overall market expansion in emerging and global economies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biliary Tumor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biliary Tumor Market Segments Analysis

Global biliary tumor market is segmented by tumor type, treatment, stage, end-user, distribution and region. Based on tumor type, the market is segmented into Cholangiocarcinoma (CCA), Gallbladder Cancer and Ampullary Cancer. Based on treatment, the market is segmented into Chemotherapy (Gemcitabine+Cisplatin), Targeted Therapy (FGFR2, IDH1) and Immunotherapy. Based on stage, the market is segmented into Localized, Locally Advanced and Metastatic. Based on end-user, the market is segmented into Oncology Centers and Hospitals. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biliary Tumor Market

The increasing occurrence of biliary tumors across various regions underscores the urgent need for robust therapeutic strategies, prompting an expansion of treatment options and the adoption of multidisciplinary management models by healthcare professionals. Heightened awareness among patients and clinicians facilitates earlier diagnosis and fosters a proactive approach toward both established and innovative interventions. This trend not only accelerates development timelines but also enhances distribution networks for market participants, further driving global growth. Additionally, a collaborative environment between academia and industry, along with improved knowledge sharing and expedited regulatory approvals, significantly contributes to the overall momentum of the biliary tumor market.

Restraints in the Global Biliary Tumor Market

The global biliary tumor market faces significant challenges due to the elevated costs associated with targeted therapies, which create financial obstacles for both patients and healthcare systems. Such high expenses often hinder the adoption of these advanced treatments, pushing providers towards conventional therapies instead of innovative options. This trend limits manufacturers' revenue potential, adversely affecting their capacity to invest in research and development for new products. Furthermore, the financial strain influences health policy decisions, prompting a more cautious stance towards integrating expensive therapies into standard care practices, ultimately constraining the overall growth prospects of the market.

Market Trends of the Global Biliary Tumor Market

The global biliary tumor market is witnessing a significant trend towards integrated genomic profiling, which enhances the precision of molecular characterization in patients. This evolution enables healthcare providers to develop personalized treatment strategies that improve outcomes while reducing adverse effects. Consequently, pharmaceutical companies are increasingly focused on expanding their pipeline of targeted therapies, while diagnostic firms invest in developing robust companion tests, fostering a collaborative ecosystem that accelerates drug adoption across various regions. This synergy not only facilitates more streamlined decision-making for clinicians but also aligns with payers' objectives to implement cost-effective, outcome-driven payment models in the management of biliary tumors.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Biliary Tumor Market Size by Tumor Type & CAGR (2026-2033)

• Market Overview
• Cholangiocarcinoma (CCA)
• Gallbladder Cancer
• Ampullary Cancer

Global Biliary Tumor Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Chemotherapy (Gemcitabine+Cisplatin)
• Targeted Therapy (FGFR2, IDH1)
• Immunotherapy

Global Biliary Tumor Market Size by Stage & CAGR (2026-2033)

• Market Overview
• Localized
• Locally Advanced
• Metastatic

Global Biliary Tumor Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Oncology Centers
• Hospitals

Global Biliary Tumor Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Biliary Tumor Market Size & CAGR (2026-2033)

• North America (Tumor Type, Treatment, Stage, End-User, Distribution)
  • US
  • Canada
• Europe (Tumor Type, Treatment, Stage, End-User, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Type, Treatment, Stage, End-User, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Type, Treatment, Stage, End-User, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Type, Treatment, Stage, End-User, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Incyte Corporation (Pemigatinib)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (Imfinzi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agios Pharmaceuticals (Ivosidenib)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QED Therapeutics (Infigratinib)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deciphera Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Relay Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Basilea Pharmaceutica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TransEnterix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Turning Point Therapeutics (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elevation Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inhibrx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pieris Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prelude Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• G1 Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations